Shanghai Xiao Fang Pharmaceutical Co., Ltd.SSE: 603207

Announcement on Voluntary Disclosure of Cooperation with Shanghai Skin Disease Hospital to Develop Class 1.1 New Traditional Chinese Medicine Compound Platycladus Orientalis Tincture for the Treatment of Hair Loss

· Issued by Shanghai Xiao Fang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-cooperation-with-shanghai-skin-disease-hospital-to-develop-class-11-new-traditional-chinese-medicine-compound-platycladus-orientalis-tincture-for-the-treatment-of-hair-loss

Announcement on Voluntary Disclosure of Cooperation with Shanghai Skin Disease Hospital to Develop Class 1.1 New Traditional Chinese Medicine Compound Platycladus Orientalis Tincture for the Treatment of Hair Loss

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Shanghai Xiao Fang Pharmaceutical Co., Ltd. on 6ix

Earlier from Shanghai Xiao Fang Pharmaceutical

Later from Shanghai Xiao Fang Pharmaceutical

All Shanghai Xiao Fang Pharmaceutical news releases